CN107328937A - For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions - Google Patents

For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions Download PDF

Info

Publication number
CN107328937A
CN107328937A CN201710734659.3A CN201710734659A CN107328937A CN 107328937 A CN107328937 A CN 107328937A CN 201710734659 A CN201710734659 A CN 201710734659A CN 107328937 A CN107328937 A CN 107328937A
Authority
CN
China
Prior art keywords
cell
patient
hepatitis
cell functions
clinical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710734659.3A
Other languages
Chinese (zh)
Inventor
曾首杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pu Xi (guangzhou) Biological Immune Technology Co Ltd
Original Assignee
Pu Xi (guangzhou) Biological Immune Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pu Xi (guangzhou) Biological Immune Technology Co Ltd filed Critical Pu Xi (guangzhou) Biological Immune Technology Co Ltd
Priority to CN201710734659.3A priority Critical patent/CN107328937A/en
Priority to PCT/CN2017/099120 priority patent/WO2019037106A1/en
Publication of CN107328937A publication Critical patent/CN107328937A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides a kind of construction method for being used to evaluate the practicality model of hepatitis B hepatopathy NK cell functions, it includes：(1) hepatitis B hepatopath is divided into chronic hepatitis of active stage patient and chronic hepatitis nonmobile phase patient, the frequency disribution of peripheral blood NK cell and its subgroup is detected using Flow Cytometry, and be compared；(2) cytokine levels of peripheral blood NK cell and its subgroup secretion are detected using Flow Cytometry, and are compared；(3) clinical indices of patient are collected, clinical indices and NK cellular immunities evaluation index are subjected to correlation analysis；(4) enlivened with NK cell functions and NK cell functions are low for feedback variable, the index relevant with patient's NK cell function states is gone out using multipie logistic regression model discrimination；(5) assessment models are set up；(6) nomogram is built.

Description

For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions
Technical field
The invention belongs to biomedical sector, and in particular to a kind of practicality for being used to evaluate hepatitis B hepatopathy NK cell functions Model and its construction method.
Technical background
NKT (natural killer, NK) cell is the important immunocyte of body, from unlike T cell its Killing activity is limited without MHC, independent of antibody, therefore referred to as Nk Cell Activity cell；NK cells are resisting tumour, antiviral Infection and immunological regulation play a significant role, be human defense's pathogen invasion and internal cytometaplasia occur first prevent Line.According to the difference of NK cell surface CD56 density, CD56 can be classified asbrightAnd CD56dimTwo kinds of hypotypes.The work(of NK cells It can include：(a) Nk Cell Activity：Target cell is recognized by non-specificity and killing medium, such as perforin is discharged (Perforin), NK cytotoxic factors, TNF (TNF-α) etc..NK cell activations are by inhibition and Activating receptor Between balance controlled.(b) secrete cytokines, the NK cells of activation can synthesize and secrete cytokine profiles, and performance is exempted from Epidemic disease adjustment effect.
NK cells are very abundant in normal liver, account for the 31% of liver endolymph cell.NK cells are in liver in microenvironment Cytokine mediated, including IL-2, IL-12, IFN-γ；NK cells cause liver thin as effector cell through FasL-Fas systems Contain perforin and granzyme in born of the same parents' apoptosis, cytoplasmic granule, and secrete cytokines IFN-γ and TNF-α suppress pathogenic infection Or tumour.Therefore, NK cells are removing tumour cell, virus infected cell, some autologous tissue's cells (such as haemocyte), parasitism Worm etc. plays key player, is that body is antitumor, one of anti-infectious important immune factor main defence line, especially chronic The serious disease progressive stage such as inflammation, tumour, internal T cell function is collapsed, and the effect of NK cells is even more important.Therefore, it is objective Evaluate NK cell functions most important to morbid state assessment, medicine for treatment guidance, Index for diagnosis.
However, lacking the clinical detection model for evaluating hepatopathy NK cell general functions at present.
Liver is the maximum immune organ of human body, and pathologic liver is full of and infiltrated a large amount of immunocytes, clinical liver disease knot Office and the reparation and improvement of vivo immunization function are closely bound up.However, in many chronic liver diseases and liver cancer patient body, with life The development of life group, the correlation technique of immune system is constantly improved, and immunoglobulin, complement since the seventies etc. are determined, The immune state of body can be estimated roughly and indirectly, progressively substituted by the detection of lymphocyte subgroup, cell factor, generation The detection means of table includes：(1) biological method detected based on DNA, such as PCR, RNA trace, in situ hybridization technology, this Class method can be detected to single immune cell factor, and study its regulatory pathway, but should not be used as clinical complicated case Differentiation；(2) bioactivity detection method, such as ELISA, ELISPOT, this kind of method is only to single cell or single immune Cell-secretion factor is detected, rather than the mean cytokine levels of certain a group immunocyte are detected, equally, also not Beneficial to the differentiation as clinical complicated case；(3) Flow Cytometry and liquid chip detection：This is more accurately to examine at present Multiple cell factors can be detected, clinician is according to immune state of the different cytokines level to patient by survey technology Estimated, but be not directed to immunocyte general function evaluation.
It can be seen that, the method that all detection techniques of the above are all evaluated without reference to immunocyte general function, while can not Multiple cell factors are detected, so that clinician is carried out in advance according to different cytokines level to the immune state of patient Estimate, and with stronger subjectivity, fairly expensive, cumbersome, it is impossible to extensive use.
The content of the invention
The purpose of the present invention is that the technical problem to be solved simply and easily is used to evaluate second there is provided a kind of for more than The construction method of the practicality model of liver hepatopathy NK cell functions, the assessment models built by this method being capable of accurate evaluation second The general function of liver hepatopathy NK cells.
In order to realize above goal of the invention, the invention provides a kind of practicality for being used to evaluate hepatitis B hepatopathy NK cell functions The construction method of property model, it includes：
(1) hepatitis B hepatopath is divided into chronic hepatitis of active stage patient (CA) and chronic hepatitis nonmobile phase patient (CAN) frequency disribution of peripheral blood NK cell and its subgroup, is detected using Flow Cytometry, and carries out the comparison between two groups；
(2) cytokine levels of peripheral blood NK cell and its subgroup secretion are detected using Flow Cytometry, and are carried out Comparison between two groups；
(3) the clinical indices demography of patient, virology, liver function, liver hardness values are collected, by clinical indices with NK cellular immunities evaluation index carries out correlation analysis, finds out the clinical indices of Close relation；
(4) enlivened with NK cell functions and NK cell functions are low for feedback variable, utilize multipie logistic regression Model filters out the index relevant with patient's NK cell function states from 14 clinic easily obtained-virology indexs.It is preferred that Ground, the method for screening is progressively Variable Selection method, and the standard of screening is AIC.In another preferred embodiment, using about stepping on Index (Youden Index), determines the optimal cutoff values for the probability that patient immune function is active group, patient is divided into NK cell functions active group and low group of NK cell functions；
(5) with Age, Fibriscan, HBeAg, HBcAb, ALB clinic-virology Index Establishment assessment models：
Estimate Std.Error Pr(>|z|)
(Intercept) 8.079761402 4.561524966 0.076513297
age 0.025878032 0.028016963 0.355665519
fibriscan 0.372221664 0.159550049 0.019650975
HBeAg -0.000459896 0.000281939 0.102850506
HBcAb -2.41486034 0.585470381 3.71E-05
ALB -0.184567872 0.089708896 0.039646921
Wherein, Age is the age；Fibriscan is liver hardness number；HBeAg is hepatitis B E antigens；HBcAb is anti-for hepatitis B core Body；ALB is albumin.
(6) nomogram is built, the clinical practice type equation for evaluating NK cell functions is obtained, uses routine clinical index The general function state of NK cells is pointed out indirectly.
Preferably, construction method of the invention also includes verification step.
It is highly preferred that the construction method of the present invention carries out external certificate using new patient's queue to model.
Preferably, the clinical practice type equation for evaluating NK cell functions is：
By calculating, the numerical value obtained is compared with cutoff values (0.0361),>=0.0361 represents that N cell functions are lived Jump；It is low for NK cell functions less than 0.0361.
Compared with prior art, method of the invention is built Model Practical, conveniently, simply, being capable of each NK of effective evaluation Cell entirety immune state, is that clinical state assessment, immunization therapy and antiviral therapy etc. provide indirect reference, promotes hepatopathy Diagnosis and treatment further precision.
Brief description of the drawings
Fig. 1 shows the frequency disribution for NK cells and its hypotype.
Fig. 2 shows NK cells and its subgroup secretion activity cell factor IFN-γ and TNF-α analysis.
Fig. 3 indicates NK cells and its hypotype secretes correlation between each cell factor and clinical virology index.
Fig. 4 shows ROC curve analysis chart.
Fig. 5 shows nomogram.
Fig. 6 shows the constructing technology route map of the applied model of NK cell functions.
Embodiment
With reference to specific embodiments and the drawings, technical scheme is further described, but the present invention is not It is limited to following examples.Such as unspecified, involved in the present invention detection technique, such as flow cytometry is known in the art Technology.
In view of the deficiency of immunologic function detection means at present, invention thinking of the invention is：By thin to hepatopath NK Born of the same parents and its reactivity cell factor of subgroup secretion, mainly IFN-γ and TNF-α；Progress passes through list on cellular and molecular level Clonal antibody carries out multi-parameter, quick quantitative analysis to individual cells or other biological particle and detected；Then statistical analysis, The overall immune state of NK cells of each natural history period patient is reappraised, and converts and establishes that can to assess NK cells overall The clinical practice Rating Model of immune state.It is intended to using this easy, practicality model, it is overall that individuation evaluates patient NK cells Immune state, is that clinical state is assessed, immunization therapy and antiviral therapy etc. provide reference, promotes the diagnosis and treatment of hepatopathy towards precision Further.
Generally, method of the invention is related to as follows：
1st, queue is studied：800 hepatitis B hepatopaths are included, diagnostic criteria was with reference to U.S.'s hepatopathy Guide to research in 2016.
Verify queue：300 hepatopaths.
2nd, study population is grouped according to above-mentioned guide：Chronic hepatitis of active stage patient (CA, 400) and Chronic Liver Scorching nonmobile phase patient (CAN, 400)；Utilize Flow Cytometry detection peripheral blood NK cell subgroup frequency (total NK cells,NKdim cells and NKbrightCells) and secretion cell factor (IFN-γ and TNF-αs), and carry out two Comparison between group.As shown in figure 1, being NK cells and its frequency disribution of hypotype.Wherein, the A in Fig. 1 shows representational NK Cell streaming detection technique；B, C, D respectively illustrate overall NK cells and its subgroup (NKdimAnd NKbright) in two groups of hepatopathys Level compare.CA is chronic hepatitis of active stage study subject, and CAN is chronic hepatitis nonmobile phase study subject, and HC is health Control.
3rd, the cytokine levels of peripheral blood NK cell and its subgroup secretion are detected using Flow Cytometry, and carry out two Comparison between group.As shown in Fig. 2 being NK cells and its analysis of subgroup secretion activity cell factor IFN-γ and TNF-α.Wherein, A in Fig. 2, which is shown, compares NK cells and the reactivity factor level of subgroup secretion in chronic liver disease；B then shows two groups of diseases The distribution map of example NK cells and its subgroup secretion of gamma-IFN and the level of TNF-α.
4th, the data such as the demography of each case, virology, liver function, liver hardness values in collection research queue, Clinical indices and NK cellular immunities evaluation index are subjected to correlation analysis, the clinical indices of Close relation are found out.Such as Fig. 3 It is shown, it is the surface of NK cells and its subgroup secrete cytokines (reactivity cell factor, the inhibitory cells factor) and expression Acceptor (Activating receptor, Inhibitory receptor) and the correlation analysis of clinical indices.Wherein dark-shaded shows that two kinds have phase Guan Xing, correlation is stronger, and color is deeper；Blank then represents that correlation is not present.
5th, with NK cell functions active (high NK activity, NK-H) and low (the low NK of NK cell functions Activity, NK-L) it is feedback variable, the clinic-virology easily obtained from 14 using multipie logistic regression model The index relevant with patient's NK cell function states is filtered out in index.The method of screening is progressively Variable Selection method, screening Standard is AIC.Using youden index (Youden Index), it is determined that " patient immune function is High group probability " is most Patient, is divided into excessive risk group and low-risk group by good cutoff values.As shown in figure 4, being ROC curve analysis chart：Chronic liver disease In sift out tool significance clinical indices, specificity and sensitivity analysis as indirect assessment NK cell functions.Institute The AUC areas for having research object are 0.818, and the AUC areas of non-hepatitis active patient group are 0.7608.
6th, 4 important clinic-virology indexs (Fibrosis value, HBsAg, HBcAb, ALB) are finally given：Build Vertical assessment models：
Estimate Std.Error Pr(>|z|)
(Intercept) 8.079761402 4.561524966 0.076513297
age 0.025878032 0.028016963 0.355665519
fibriscan 0.372221664 0.159550049 0.019650975
HBeAg -0.000459896 0.000281939 0.102850506
HBcAb -2.41486034 0.585470381 3.71E-05
ALB -0.184567872 0.089708896 0.039646921
7th, nomogram (nomograms) is built, the clinical practice type equation for evaluating NK cell functions is obtained, using normal Rule clinical indices point out the general function state of NK cells indirectly.
Nomogram is as shown in Figure 5.
Clinical practice type equation for evaluating NK cell functions is：
By calculating, the numerical value obtained is compared with cutoff values (0.0361),>=0.0361 represents that N cell functions are lived Jump；It is low for NK cell functions less than 0.0361.
8th, external certificate is carried out to assessment models using new patient's queue.
Application Example
Example one：Routine clinical biochemistry detection is carried out to 12 Chronic Hepatitis Bs, its NK cellular immune function is understood：
The partial clinical index of 12 cases is as follows：
Case/index Age HBeAg HBcAb ALB Fibrosis
1 33 34 1.6 43 5.4
2 23 2 10.7 44 5.2
3 25 46 32.5 43 6.2
4 45 35 0.007 39 7.8
5 34 36 4.5 51 6.3
6 38 0.34 0.3 48 6.8
7 54 0.45 0.67 41 4.7
8 62 0.63 0.76 43 3.5
9 25 47 21.2 49 8.5
10 41 0.32 0.056 41 12.3
11 67 0.32 0.045 40 9.8
12 45 0.12 0.021 39 6.9
(2) assessment models (Vnk models) of the invention more than, the NK cell functions detected value of 12 cases is such as Under：
Case 1 2 3 4 5 6 7 8 9 10 11 12
Vnk 0.2944 8.6199 -28.1683 0.9927 0.0001 0.8818 0.8850 0.7712 4.6581 0.9976 0.9975 0.9887
(3) it is 0.0361, Vnk according to the cutoff values of Vnk models>=0.0361 represents that NK cell functions are normal or active (NK-H)；Vnk<0.0361 represents that NK cell functions are low (NK-L), and the NK cell functions state of above-mentioned case is judged such as with this Under：
Example two：Hepatitis B liver cancer patient, male, 35 years old, check clinical indices in operative treatment half a year, carry out virology and The sequence inspection of biochemical indicator, timing node is：0 week, 12 weeks, 24 weeks.
(1) clinical indices are as follows：
(2) according to the NK cell function evaluation models of the present invention, in the Vnk values of different time points, i.e. NK cellular immunities work( Energy testing result is as follows：
Treatment time point 0 week 12 weeks 24 weeks
Vnk 0.9255 0.9426 0.9871
(3) it is 0.0361, Vnk according to the cutoff values of Vnk models>=0.0361 represents that NK cell functions are normal or active (NK-H)；Vnk<0.0361 represents that NK cell functions are low (NK-L), and the NK cell functions state of above-mentioned case is judged such as with this Under：
Therefore, from above example it can be confirmed that the NK cell application assessment models of the present invention not only may determine that single The overall immune functional state of instantaneous NK cells；Further, the NK in non-treatment or therapeutic process can be monitored The variation tendency of cell entirety immunologic function；Because the present invention builds single thin based on advanced Flow Cytometry and airflow classification The detection technique of born of the same parents, numerical value is true and reliable；Biochemical, virology index is merged again, using the computational methods of biometrics big data, The structure of model is carried out, it is convenient, practical, accurate.
It is worth noting that, the method for the present invention is intended to build the mould for being used for detecting and assess NK lymphocyte immunity states Type, direct purpose is only in that acquisition intermediate result, and the diagnosis of the intermediate result and disease or health status have no direct certainty Contact.Treatment and diagnosis for hepatitis B diseases are, it is necessary to the numerous parameters of overall merit, including are not limited to Hepatitis B Surface and resist The multinomial serology response such as original, surface antibody, e antigens, e antibody, core antibody, pre S 1 antigen level and biochemical response, And the NK lymphocyte immunities state only known via model involved in the present invention directly can not be detected and/or examined Disconnected hepatitis B diseases.

Claims (6)

1. a kind of construction method for being used to evaluate the practicality model of hepatitis B hepatopathy NK cell functions, it is characterised in that including：
(1) hepatitis B hepatopath is divided into chronic hepatitis of active stage patient and chronic hepatitis nonmobile phase patient, it is thin using streaming The frequency disribution of born of the same parents' technology for detection peripheral blood NK cell and its subgroup, and carry out the comparison between two groups；
(2) cytokine levels of peripheral blood NK cell and its subgroup secretion are detected using Flow Cytometry, and carry out two groups Between comparison；
(3) the clinical indices demography of collection patient, virology, liver function, liver hardness values, thin with NK by clinical indices Born of the same parents' immunity evaluation index carries out correlation analysis, finds out the clinical indices of Close relation；
(4) enlivened with NK cell functions and NK cell functions are low for feedback variable, utilize multipie logistic regression model The index relevant with patient's NK cell function states is filtered out from multiple clinic-virology indexs easily obtained；
(5) with Age, Fibrosis detected value, HBeAg, HBcAb, ALB clinic-virology Index Establishment assessment models：
Estimate Std.Error Pr(>|z|) (Intercept) 8.079761402 4.561524966 0.076513297 age 0.025878032 0.028016963 0.355665519 fibriscan 0.372221664 0.159550049 0.019650975 HBeAg -0.000459896 0.000281939 0.102850506 HBcAb -2.41486034 0.585470381 3.71E-05 ALB -0.184567872 0.089708896 0.039646921
Wherein, Age is the age；Fibriscan is liver hardness number；HBeAg is hepatitis B E antigens；HBcAb is hepatitis B core antibody； ALB is albumin；
(6) nomogram is built, the clinical practice type equation for evaluating NK cell functions is obtained, it is indirect using routine clinical index Point out the general function state of NK cells.
2. according to the method described in claim 1, it is characterised in that also including verification step.
3. method according to claim 2, it is characterised in that：External certificate is carried out to model using new patient's queue.
4. according to the method described in claim 1, it is characterised in that：Clinical practice type equation for evaluating NK cell functions For：
5. according to the method described in claim 1, it is characterised in that：In the step (4), the method for screening is that progressively variable is sieved Method is selected, the standard of screening is AIC.
6. according to the method described in claim 1, it is characterised in that：In the step (4), determine that patient exempts from using youden index Epidemic disease function is the optimal cutoff values of the probability of active group, and the critical value is 0.0361, and patient, which is divided into NK cell functions, to live Jump group and low group of NK cell functions.
CN201710734659.3A 2017-08-24 2017-08-24 For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions Pending CN107328937A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710734659.3A CN107328937A (en) 2017-08-24 2017-08-24 For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions
PCT/CN2017/099120 WO2019037106A1 (en) 2017-08-24 2017-08-25 Method for constructing practical model for evaluating nk cell function in hepatitis b liver disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710734659.3A CN107328937A (en) 2017-08-24 2017-08-24 For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions

Publications (1)

Publication Number Publication Date
CN107328937A true CN107328937A (en) 2017-11-07

Family

ID=60224755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710734659.3A Pending CN107328937A (en) 2017-08-24 2017-08-24 For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions

Country Status (2)

Country Link
CN (1) CN107328937A (en)
WO (1) WO2019037106A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108663510A (en) * 2018-04-28 2018-10-16 璞晞（广州）生物免疫技术有限公司 The check and evaluation method and kit of hepatopathy NK cell functions
CN111312387A (en) * 2020-01-16 2020-06-19 安徽医科大学第一附属医院 Model for predicting severity of pain of male chronic prostatitis/chronic pelvic pain syndrome and establishment of model
CN112336358A (en) * 2020-04-30 2021-02-09 中山大学孙逸仙纪念医院 Model for predicting malignant risk of breast lesion of compact breast and construction method thereof
CN112885473A (en) * 2021-04-16 2021-06-01 杭州普罗亭医学检验实验室有限公司 Pan-disease risk prediction system combining high-dimensional immunity with big data and artificial intelligence

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105021761A (en) * 2015-07-02 2015-11-04 华中农业大学 Method for determination of a variety of organic acids in grape juice and authenticity of grape juice

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1444043A (en) * 2002-12-25 2003-09-24 帕弗瑞生物技术(北京)有限公司 Individuation specific immunocytofunction determination method
WO2006085984A2 (en) * 2004-07-09 2006-08-17 Amaox, Inc. Immune cell biosensors and methods of using same
ITVR20050045A1 (en) * 2005-04-14 2006-10-15 Riccardo Ortolani PROCEDURE FOR CLINICAL ANALYSIS OF A COMPARATIVE TYPE
CN102024090A (en) * 2009-09-14 2011-04-20 深圳市嘉实特科技有限公司 Hepatitis B indicator data processing device, detection equipment and detection system
EP3058369B1 (en) * 2014-01-06 2020-06-17 Liposcience, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
CN106227996A (en) * 2016-07-14 2016-12-14 浙江大学 A kind of construction method of clinical information quantization system
CN106943192A (en) * 2017-03-14 2017-07-14 上海交通大学医学院附属第九人民医院 The method for building up of the preoperative forecast model of the expression index of lung carcinoma cell KI 67

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105021761A (en) * 2015-07-02 2015-11-04 华中农业大学 Method for determination of a variety of organic acids in grape juice and authenticity of grape juice

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XIAOYAN LI ET AL.: "A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection", 《SCIENTIFIC REPORTS》 *
吴韶飞 等: "NK 细胞和NKT 细胞在慢性乙型肝炎中的表型和功能特征", 《细胞与分子免疫学杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108663510A (en) * 2018-04-28 2018-10-16 璞晞（广州）生物免疫技术有限公司 The check and evaluation method and kit of hepatopathy NK cell functions
CN111312387A (en) * 2020-01-16 2020-06-19 安徽医科大学第一附属医院 Model for predicting severity of pain of male chronic prostatitis/chronic pelvic pain syndrome and establishment of model
CN112336358A (en) * 2020-04-30 2021-02-09 中山大学孙逸仙纪念医院 Model for predicting malignant risk of breast lesion of compact breast and construction method thereof
CN112885473A (en) * 2021-04-16 2021-06-01 杭州普罗亭医学检验实验室有限公司 Pan-disease risk prediction system combining high-dimensional immunity with big data and artificial intelligence

Also Published As

Publication number Publication date
WO2019037106A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
CN107328937A (en) For the construction method for the practicality model for evaluating hepatitis B hepatopathy NK cell functions
Sommerfeld et al. Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis
Peruzzi et al. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS‐CoV‐2 infection
Khaiboullina et al. Cytokine expression provides clues to the pathophysiology of Gulf War illness and myalgic encephalomyelitis
Yamada et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis
Van Hamburg et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent
CN107545135B (en) The construction method of hepatitis B liver diseases T lymphocyte immune state application assessment models
Kong et al. Increased expressions of IL-22 and Th22 cells in the coxsackievirus B3-induced mice acute viral myocarditis
Brouard et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy
Didier et al. Immune correlates of aging in outdoor-housed captive rhesus macaques (Macaca mulatta)
CN105683392A (en) Dendritic cell response gene expression, compositions of matters and methods of use thereof
An et al. The effect of biological agent treatment on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, and C-reactive protein in psoriasis patients
Goropevšek et al. STAT signaling as a marker of SLE disease severity and implications for clinical therapy
Kish et al. IL-1 receptor signaling is required at multiple stages of sensitization and elicitation of the contact hypersensitivity response
Byng-Maddick et al. Tumor necrosis factor (TNF) bioactivity at the site of an acute cell-mediated immune response is preserved in rheumatoid arthritis patients responding to anti-TNF therapy
Mearns et al. IL‐25 exhibits disparate roles during Th2‐cell differentiation versus effector function
US20160275236A1 (en) Analyzing Immune Signaling Networks for Identification of Therapeutic Targets in Complex Chronic Medical Disorders, Identification of a Natural Killer Cell Population as a Potential Therapeutic Target for Gulf War Illness And Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, And Modulation of Natural Killer Cell Function by Stimulation with Interleukin 15
Ramirez et al. Deriving a Boolean dynamics to reveal macrophage activation with in vitro temporal cytokine expression profiles
CN103097549A (en) Method of determining kidney transplantation tolerance
Oyoshi et al. Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus
Uller et al. Viral induced overproduction of epithelial TSLP: role in exacerbations of asthma and COPD?
CN108884497A (en) The clinically relevant object of immunization therapy effect
Prosty et al. In silico identification of immune cell-types and pathways involved in chronic spontaneous urticaria
Wang et al. Exploring machine learning methods for predicting systemic lupus erythematosus with herpes
CN115184614B (en) Use of immune efficacy or clinical relative immune efficacy in evaluating vaccine response intensity in a subject

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171107

RJ01 Rejection of invention patent application after publication